Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2023-173040

Published: 2023

Journal Articles

The Impact of Leukapheresis Collection on Patients Undergoing Chimeric Antigen T-Cell Receptor Therapy with Tisagenlecleucel

Sanila Sarkar, Jeremy S Connors, Irtiza Sheikh, Emily Rav, Zhongya Wang, Roland L. Bassett, Morgan Straubel, Kris Michael Mahadeo, Priti Tewari, Demetrios Petropoulos, Chitra Hosing, Dristhi Ragoonanan, Sajad Khazal, Arthur Fucanan, Christofer Bibal

Blood (2023) 142 (Supplement 1): 6944.

https://doi.org/10.1182/blood-2023-180879

Published: 2023

Journal Articles

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Blood (2023) 142 (Supplement 1): 774.

https://doi.org/10.1182/blood-2023-172980

Published: 2023

Journal Articles

Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study

Blood (2018) 132 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2018-99-113439

Published: 2018

Journal Articles

Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

Issa F. Khouri, Jorge A Borin Scutti, Denái R. Milton, Courtney Nicholas, Mariana Pineda, Elias J. Jabbour, MD, Roland L. Bassett, Jr., Shalini S Yadav, Luis M Vence, James P Allison, PhD, Alison Gulbis, Padmanee Sharma, MD PhD

Blood (2018) 132 (Supplement 1): 4585.

https://doi.org/10.1182/blood-2018-99-117814

Published: 2018

Journal Articles

Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies

Issa F. Khouri, Alison M. Gulbis, Denái R. Milton, Martin Korbling, MD, Celina Ledesma, Sairah Ahmed, Amin M. Alousi, MD, Betul Oran, MDMS, Paolo Anderlini, Stefan O. Ciurea, Roland L. Bassett, Jr., Elias J. Jabbour, MD

Blood (2017) 130 (Supplement 1): 3240.

https://doi.org/10.1182/blood.V130.Suppl_1.3240.3240

Published: 2017

Journal Articles

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results

Issa F. Khouri, Elias J. Jabbour, MD, Celina Ledesma, Martin Korbling, MD, Amin M. Alousi, Paolo Anderlini, Betul Oran, MDMS, Stefan O. Ciurea, Luis E. Fayad, Roland L. Bassett, Jr., Alison M. Gulbis

Blood (2017) 130 (Supplement 1): 2036.

https://doi.org/10.1182/blood.V130.Suppl_1.2036.2036

Published: 2017

Journal Articles

Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT)

Issa F. Khouri, MD, Irina Fernandez Curbelo, PhD, Francesco Turturro, MD, Denái R. Milton, Rang A Kim, Elias J. Jabbour, MD, Roland L Bassett, Jr., Luis M Vence, PhD, Padmanee Sharma, MD PhD, Alison M Gulbis, PharmD

Blood (2016) 128 (22): 1164.

https://doi.org/10.1182/blood.V128.22.1164.1164

Published: 2016

Journal Articles

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2016) 128 (22): 2012.

https://doi.org/10.1182/blood.V128.22.2012.2012

Published: 2016

Journal Articles

Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial

Blood (2016) 128 (22): 500.

https://doi.org/10.1182/blood.V128.22.500.500

Published: 2016

Journal Articles

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

Issa F. Khouri, MD, Bill Erwin, MS, Alison M Gulbis, PharmD, Francesco Turturro, MD, S Cheenu Kappadath, PhD, Dustin Gress, MS, Rosamar B Valverde, Elias J. Jabbour, MD, Roland L Bassett, Jr., Aaron Jessop, MBA,MD

Blood (2016) 128 (22): 662.

https://doi.org/10.1182/blood.V128.22.662.662

Published: 2016

Journal Articles

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Blood (2015) 126 (23): 3192.

https://doi.org/10.1182/blood.V126.23.3192.3192

Published: 2015

Journal Articles

Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial

Blood (2015) 126 (23): 738.

https://doi.org/10.1182/blood.V126.23.738.738

Published: 2015

Journal Articles

Overall Survival in Hematopoietic Stem Cell Transplantation Is Not Correlated with Age of Red Cells Transfused Pre- and Post-Transplantation

Fleur M. Aung, MD, Roland L Bassett, MS, Benjamin Lichtiger, MDPhD, Emil J. Freireich, MD, Issa F Khouri

Blood (2014) 124 (21): 1213.

https://doi.org/10.1182/blood.V124.21.1213.1213

Published: 2014

Journal Articles

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD

Issa F. Khouri, Wei Wei, Martin Korbling, Francesco Turturro, Sairah Ahmed, Amin Alousi, Paolo Anderlini, Stefan Ciurea, Elias Jabbour, Betul Oran, Uday R. Popat, Gabriela Rondon, Roland L. Bassett, Jr, Alison Gulbis

Blood (2014) 124 (14): 2306–2312.

https://doi.org/10.1182/blood-2014-07-587519

Published: 2014

Journal Articles

Linezolid Use in Hematopoietic Stem Cell Transplantation: A Cautionary Tale

Alison M Gulbis, PharmD, Musa Yilmaz, MD, Dawen Sui, MS, Roland L Bassett, Jr., MS, Zandra R Rivera, RN, MS, ANP-BC, Richard E. Champlin, Marcos De Lima, MD

Blood (2012) 120 (21): 4534.

https://doi.org/10.1182/blood.V120.21.4534.4534

Published: 2012

Journal Articles

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Issa F Khouri, MD, Rima M Saliba, PhD, Martin Korbling, MD, Amin M Alousi, MD, Uday R Popat, MD, Paolo Anderlini, MD, Stefan O Ciurea, MD, Partow Kebriaei, MD, Muzaffar H. Qazilbash, MD, Richard Champlin, MD, Roland L Bassett, Jr.

Blood (2011) 118 (21): 894.

https://doi.org/10.1182/blood.V118.21.894.894

Published: 2011

Journal Articles

Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).

Issa F Khouri, Roland L Bassett, Jr., Pedro Cano, Susan O'Brien, Yvonne Hsu, Carlos E Bueso-Ramos, Robyn Harrell, Grace-Julia Okoroji, Leandro De Padua Silva, Alessandra Ferrajoli, William Wierda, Hagop Kantarjian, Richard Champlin, John McMannis, Marcelo Fernandez-Vina

Blood (2009) 114 (22): 2287.

https://doi.org/10.1182/blood.V114.22.2287.2287

Published: 2009

Journal Articles

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Blood (2009) 114 (22): 868.

https://doi.org/10.1182/blood.V114.22.868.868

Published: 2009

Journal Articles

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Issa Khouri, Roland L Bassett, Yvonne Hsu, Timothy Dickason, Sandra Acholonu, Robyn Harrell, Grace-Julia Okoroji, Leandro de Padua Silva, Martin J. Korbling, Amin M. Alousi, Chitra Hosing, Uday Popat, Sergio A. Giralt, Partow Kebriaei, Muzaffar H. Qazilbash, M.D., Celina Ledesma, Michael J. Keating, MB, BS, Richard E. Champlin, Carlos Bueso-Ramos

Blood (2008) 112 (11): 1128.

https://doi.org/10.1182/blood.V112.11.1128.1128

Published: 2008

NARROW

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

The Impact of Leukapheresis Collection on Patients Undergoing Chimeric Antigen T-Cell Receptor Therapy with Tisagenlecleucel

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study

Durable Responses with Ipilimumab Plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies

Safety of Addition of Inotuzumab Ozogamicin (CMC 544) to Bendamustine, Fludarabine, and Rituximab (BFR) Allogeneic Conditioning for Lymphoid Malignancies

Bfr (bendamustine, fludarabine, rituximab) Nonmyeloablative Allogeneic Conditioning for Lymphoid Malignancies: 8-Year Results

Lenalidomide with Ipilimumab for Lymphoid Malignancies after Allogeneic or Autologous Stem Cell Transplantation (SCT)

Defining the Immune Checkpoint Landscape in the Bone Marrow and Peripheral Blood of Patients with Chronic Lymphocytic Leukemia (CLL)

Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial

Stratified Intense-Dose- Yttrium-90 Ibritumumab Tiuxetan ( 90 YIT ) with Bendamustine+Fludarabine Nonmyeloablative Conditioning for Allogeneic Stem Cell Transplantation in b-Cell Malignancies

In-Vivo Purging with Rituximab (R) Followed By Z/BEAM Vs BEAM/R Autologous Stem Cell Conditioning for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) Patients (pts): Mature Results from a Combined Analysis of 3 Trials

Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial

Overall Survival in Hematopoietic Stem Cell Transplantation Is Not Correlated with Age of Red Cells Transfused Pre- and Post-Transplantation

BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD

Linezolid Use in Hematopoietic Stem Cell Transplantation: A Cautionary Tale

Nonmyeoablative Allogeneic Conditioning with Bendamustine in Combination with Fludarabine and Rituximab for Lymphoid Malignancies: Immunosuppression without Myelosuppression and without Acute Gvhd

Human-Leukocyte-Histocompatibility Antigens (HLA-A1+, A2-, B44-) and Serum Immunoglobulin (Ig)G with CD4 Levels Predict Response to Graft-Versus-Leukemia (GVL) and Overall Survival, Respectively, After Non-Myeloablative Allogeneic Stem Transplantation (NST) for Chronic Lymphocytic Leukemia (CLL).

Stem Cell Transplantation with 90 yttrium Ibritumomab Tiuxetan( 90 YIT) in Non-Hodgkin's Lymphoma (NHL): Observations From PET Pre-Treatment Imaging and Responses in Allografted Refractory Follicular Histologies.

Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only